TB-500 corresponds to the actin-binding region of thymosin 4, an actin-sequestering peptide described as supporting cell migration, reducing inflammation and encouraging new-vessel formation in wound-healing assays [4] [5]
Gastrointestinal Studies BPC-157 was originally isolated from gastric juice, and much of the early research focused on GI models: Cytoprotection: Multiple rodent studies have demonstrated protective effects on gastric mucosa in lesion models (Sikiric et al., 1993, 1994)
maximum 2 mg/kg)
However, the evidence for PRP is somewhat stronger, and it has been used more extensively in clinical practice
Larger mixing volumes result in lower levels, needing larger injection volumes but possibly longer shelf life and easier measurement of small doses
TB-500 contributes actin-binding and anti-apoptotic effects that widen the therapeutic scope beyond what GHK-Cu alone provides